Biography

Jonathan Dowell, M.D., is an Assistant Professor in the Department of Internal Medicine at UT Southwestern, and a member of the Division of Hematology and Oncology. He is the Program Director of the Hematology and Oncology Fellowship Program. He also serves as Chief of Hematology/Oncology at the Dallas VA Medical Center.

Dr. Dowell specializes primarily in thoracic malignancies, including non-small cell and small cell lung cancers, mesothelioma, and thymoma.

Dr. Dowell earned his bachelor’s degree in neuroscience from Amherst College in Massachusetts, where he graduated magna cum laude. He received his medical degree from the University of Chicago’s Pritzker School of Medicine and completed internal medicine residency training at UT Southwestern Medical Center. He then completed advanced training through a fellowship in hematology and oncology at Vanderbilt University in Nashville.

Certified by the American Board of Internal Medicine in hematology and in oncology, Dr, Dowell joined the UT Southwestern faculty in 1996.

Dr. Dowell’s research interests include thoracic malignancies. His investigations have resulted in 40 publications in peer-reviewed journals and contributions to more than 30 book chapters, reviews, editorials, and case reports. Additionally, he has presented his findings at scientific conferences throughout the United States and internationally.

At UT Southwestern, Dr. Dowell chairs the Simmons Cancer Center Data and Safety Monitoring Committee and co-chairs the Dallas VA Transfusion Utilization Committee and the Veterans Integrated Service Network 17 Hematology/Oncology Work Group.

Dr. Dowell is active in several professional societies, including the American Society of Clinical Oncology, the American Society of Hematology, the Texas Medical Association, and the Dallas County Medical Society.

Personal Note

Dr. Dowell's interests outside of medicine include travel, baseball, and family activities.

Education

Medical School
University of Chicago Pritzker School of Medicine (1993)
Internship
UT Southwestern Medical Center (1994), Internal Medicine
Residency
UT Southwestern Medical Center (1996), Internal Medicine
Fellowship
Vanderbilt University Medical Center (2000), Hematology Oncology

Publications

Featured Publications LegendFeatured Publications

Upper Extremity Venous Thrombosis in Patients With Cancer With Peripherally Inserted Central Venous Catheters: A Retrospective Analysis of Risk Factors
Ahn DH, Illum HB, Wang DH, Sharma A, and Dowell JE JOP 2013 5
A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma.
Dowell JE, Dunphy FR, Taub RN, Gerber DE, Ngov L, Yan J, Xie Y, Kindler HL Lung Cancer 2012 Sep 77 3 567-71
Consent timing and experience: modifiable factors that may influence interest in clinical research.
Gerber DE, Rasco DW, Skinner CS, Dowell JE, Yan J, Sayne JR, Xie Y J Oncol Pract 2012 Mar 8 2 91-6
ERCC1 expression and outcomes in head and neck cancer treated with concurrent cisplatin and radiation.
Hayes M, Lan C, Yan J, Xie Y, Gray T, Amirkhan RH, Dowell JE Anticancer Res. 2011 Dec 31 12 4135-9
Predictors and impact of second-line chemotherapy for advanced non-small cell lung cancer in the United States: real-world considerations for maintenance therapy.
Gerber DE, Rasco DW, Le P, Yan J, Dowell JE, Xie Y J Thorac Oncol 2011 Feb 6 2 365-71
Looking beyond surveillance, epidemiology, and end results: patterns of chemotherapy administration for advanced non-small cell lung cancer in a contemporary, diverse population.
Rasco DW, Yan J, Xie Y, Dowell JE, Gerber DE J Thorac Oncol 2010 Oct 5 10 1529-35
Small cell lung cancer: are we making progress?
Dowell JE Am. J. Med. Sci. 2010 Jan 339 1 68-76
The impact of consenter characteristics and experience on patient interest in clinical research.
Rasco DW, Xie Y, Yan J, Sayne JR, Skinner CS, Dowell JE, Gerber DE Oncologist 2009 May 14 5 468-75
Small-cell lung cancer: translational research enroute to therapeutic advances.
Dowell J, Minna JD Oncology (Williston Park, N.Y.) 2008 Nov 22 13 1493, 1495
Phase 1/2 dose escalating study of twice-monthly pemetrexed and gemcitabine in patients with advanced cancer and non-small cell lung cancer.
Dudek AZ, Larson T, McCleod MJ, Schneider DJ, Dowell JE, Banerjee TK, Pandya KJ, Bromund JL, Chen R, Monberg MJ, Obasaju CK J Thorac Oncol 2008 Apr 3 4 394-9

Honors & Awards

  • Internal Medicine, Core Clerkship Teaching Award
    Teaching Award (2012)
  • Eugene P. Frenkel Outstanding Teaching Award
    Teaching Award (2010)
  • ASCO
    Merit Award (2000)
  • Vanderbilt Hematology/Oncology
    Fellow Award (1998)

Professional Associations/Affiliations

  • American Society of Clinical Oncology
  • American Society of Hematology